Roche Business Development at a Glance

Last Modified Date: February 19, 2018

The Roche Group finished 2017 with a diverse run of deals in drug delivery technologies (Halozyme), antibiotic discovery (Warp Drive Bio), laboratory business analytics (Viewics), and oncology enzyme inhibitors (Ignyta). Another pharma giant might have raised eyebrows with this string of acquisitions and licensing deals, but growing interest in personalized medicine and a strong diagnostics business makes this par for the course for Roche.

Roche Stock

Roche Group
Company Type: Large Pharma
Region: Switzerland, Worldwide
Cash Position: CHF 11 997M
Therapeutic Focus: Oncology, Neuroscience, Infectious diseases, Immunology, Cardiovascular and Metabolism, Ophthalmology, Hematology, Hemophilia, Respiratory, Research Technologies, Women's Health


Deal Activity

Roche Data

Figure 1. Roche Group. In-Licensing Deals and Acquisitions, 2013 through present (February 2018)

Recent Deal Highlights:

COLLABORATION WITH MACROGENICS FOR BISPECIFIC MOLECULES FROM DART PROGRAM

Total Size: USD 380M | Upfront: USD 10M | Therapeutic Area: Oncology | Date: January 2018

PRESS

ACQUISITION OF IGNYTA FOR CANCER THERAPIES

Total Size: USD 1 700M | Therapeutic Area: Oncology | Date: December 2017

PRESS

COLLABORATION WITH WARP DRIVE BIO FOR NOVEL CLASSES OF ANTIBIOTICS

Total Size: USD 387M | Therapeutic Area: Infectious Diseases | Date: October 2017

PRESS

R&D PIPELINE

Roche Pipeline

Figure 2. Roche Group. R&D Pipeline at present (February 2018)

Products from Recent Deals

BRISTOL-MYERS SQUIBB PARTNERED ANTI-MYOSTATIN ADNECTIN

Disease Area: Neuroscience | Status: Duchenne Muscular Dystrophy Phase III

ACQUIRED SERAGON PHARMACEUTICALS NEXT GENERATION ORAL SELECTIVE ESTROGEN RECEPTOR DEGRADERS

Disease Area: Oncology | Status: ER+ Breast Cancer Phase I

NEWLINK GENETICS PARTNERED CANCER IMMUNOTHERAPY

Disease Area: Oncology | Status: Combination with Atezolizumab in Solid Tumors Phase I

BUSINESS DEVELOPMENT TEAM


Business profiles tailored to your asset.